Zynerba Pharmaceuticals

Dedicated to the development and commercialization of innovative transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neuropsychiatric conditions in patients with high unmet medical needs

Learn More

Our mission is to improve the lives of patients battling severe rare and near-rare neuropsychiatric disorders including Fragile X syndrome, certain refractory epilepsies, and Tourette Syndrome.

Our Team

Our Team

Our team has a proven track record of success in developing novel transdermal products for patients in need.

More >>

Our Development Pipeline

Our Development Pipeline

We are developing two proprietary transdermal pharmaceutically-produced products in multiple neuropsychiatric indications: a CBD gel for Fragile X syndrome and certain refractory epilepsies and a novel THC pro-drug transdermal patch.

More >>

For Investors

For Investors

Learn more about our company and our potential.

More >>

Latest News

0508

Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights

Learn More

0425

Zynerba Pharmaceuticals Announces Twelve Month ZYN002 Data from STAR 2 Study in Patients with Focal Seizures at the 2018 Annual Meeting of the American Academy of Neurology (AAN)

Learn More